Compare NLY & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NLY | PODD |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.0B |
| IPO Year | N/A | 2007 |
| Metric | NLY | PODD |
|---|---|---|
| Price | $22.06 | $235.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | $23.73 | ★ $357.65 |
| AVG Volume (30 Days) | ★ 6.4M | 964.7K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 12.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $188.83 | $24.33 |
| Revenue Next Year | $2.40 | $19.33 |
| P/E Ratio | ★ $7.88 | $68.63 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $16.60 | $233.29 |
| 52 Week High | $24.52 | $354.88 |
| Indicator | NLY | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 36.34 |
| Support Level | $20.40 | N/A |
| Resistance Level | $22.29 | $299.75 |
| Average True Range (ATR) | 0.49 | 6.35 |
| MACD | -0.09 | 0.27 |
| Stochastic Oscillator | 25.34 | 12.73 |
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.